OP 5.3 – 00082 1-year treatment with ponatinib provides protection of CD4+T cells against HIV that is maintained at least 1 year more after treatment interruption

• M. Manzanares,
• F. Ramos-Martín,
• G. Casado-Fernández,
• M. Torres,
• E. Mateos,
• L. Vigón,
• S. Rodríguez-Mora,
• V. García-Gutiérrez,
• V. Planelles,
• M. Coiras

Affiliations

M. Manzanares

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

F. Ramos-Martín

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

G. Casado-Fernández

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain; Faculty of Sciences, Universidad de Alcalá, Madrid, Spain; Biomedical Research Center Network in Infectious Diseases, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain

M. Torres

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

E. Mateos

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

L. Vigón

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

S. Rodríguez-Mora

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain; Biomedical Research Center Network in Infectious Diseases, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain

V. García-Gutiérrez

Hematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain

V. Planelles

Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA

M. Coiras

Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain; Biomedical Research Center Network in Infectious Diseases, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain